Fort Lee, New Jersey, USA, March 31, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc.(OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company and the provider of unique all botanical medicinal products (Botanical Therapeutics®) that target dermatological problems such as acne, and other major health and wellness concerns reports that its sales for the First Quarter of 2015 grew by 21% in comparison to the same period of 2014. This sales growth places the present run rate for AcnEase® sales for 2015 to approach $1,000,000.
This Quarter is also the 9th consecutive quarter of double digit sales growth for Herborium Group, and 5th consecutive quarter with an increase in the average value of the unit sales per customer. We attribute this increase to a significant expansion in the Company's international sales especially in the UK and France. The value of an average international order is about 20% higher in comparison to a domestic order, and also has a higher margin.
Herborium launched an independent French platform www.acnease.fr in February 2015 and the initial sales on this platform has exceeded expectations. .
Mobile versions of www.acnease.com launched in 2014 and a mobile version of www.acnease.fr also growing and presently account for about 25% of Internet orders. In 2014, "mobile" orders accounted for approximately 18 % of Internet orders
First Quarter of 2015 has also shown an increase in distributor's participation in revenues growing by 20% in comparison to the same period of 2014. This is a testament of a growing wholesale market interest for Herborium's products.
The steady growth in revenues, and other financial indicators such as market share, gross margin and expending distribution channels put the Company closer to executing the development plan and up listing plan announced for 2015.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, Canada, the United Kingdom, and continental Europe as well as in Australia through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, www.acnease.com and www.acnease.fr
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.